The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

The biomarkers and nosology of sleep-wake disorder medicine, as represented in the DSM-5, furnish an informative paradigm for the use of biomarkers in psychiatric practice. This article presents a case study that illustrates the relevance of sleep-related biomarkers to diagnosis, treatment monitoring, and prognosis. The biomarkers discussed in the DSM-5 sleep-wake disorders chapter have reliability as well as antecedent, concurrent, and predictive validity, making them clinically useful for personalized medicine. The optimal clinical context for the use of such biomarkers is care that is measurement based, longitudinal, team based, patient focused, and (as often as not) family centered. In addition, such biomarkers also provide important clues to etiopathogenesis.